Nintedanib in advanced NSCLC of adenocarcinoma histology: a profile of its use in the EU

2018-03-28T21:43:24Z (GMT) by Sohita Dhillon
Funding: The preparation of this review was not supported by any external funding.

Conflicts of interest: S. Dhillon is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Additional information about this Adis Drug Review can be found here.

Abstract

Nintedanib (Vargatef®) is a triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors and fibroblast growth factor receptors. In the phase 3 LUME-Lung 1 study in patients with advanced non-small cell lung cancer (NSCLC), the subgroup of patients with adenocarcinoma histology who have progressed after first line chemotherapy experienced a significant improvement in progression-free and overall survival with oral nintedanib + docetaxel relative to placebo + docetaxel, with greater benefits seen in patients with rapidly progressing disease. Nintedanib is the first antiangiogenic agent to have shown a survival benefit in the second-line treatment of these patients. Nintedanib combination therapy has a generally manageable tolerability profile. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2018